
Annual report 2025
added 02-25-2026
Soleno Therapeutics Net Debt 2011-2026 | SLNO
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Soleno Therapeutics
| 2025 | 2024 | 2023 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -19.5 M | -37.6 M | -169 M | -20.8 M | -49.1 M | -20.4 M | -23.1 M | -17.1 M | -2.73 M | -5.49 M | -7.86 M | 12.7 M | 8.98 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12.7 M | -169 M | -27 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Diagnostics research industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
1.18 M | - | -6.23 % | $ 30.6 M | ||
|
ICON Public Limited Company
ICLR
|
4.63 B | $ 98.33 | 0.9 % | $ 8.11 B | ||
|
Akumin
AKU
|
1.21 B | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
-10.9 M | - | -6.19 % | $ 10.5 M | ||
|
Brainsway Ltd.
BWAY
|
-6.88 M | $ 13.71 | -0.22 % | $ 99.4 M | ||
|
Charles River Laboratories International
CRL
|
1.98 B | $ 155.46 | 1.83 % | $ 7.71 B | ||
|
Bioventus
BVS
|
231 M | $ 8.62 | 0.23 % | $ 574 M | ||
|
DexCom
DXCM
|
-842 M | $ 64.24 | -1.56 % | $ 25.1 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
-173 M | - | - | $ 562 M | ||
|
Castle Biosciences
CSTL
|
-108 M | $ 25.56 | 0.95 % | $ 710 M | ||
|
CareDx, Inc
CDNA
|
-39.2 M | $ 17.01 | 3.4 % | $ 906 M | ||
|
Accelerate Diagnostics
AXDX
|
-33.3 M | - | -61.36 % | $ 2.46 M | ||
|
Exact Sciences Corporation
EXAS
|
-916 M | $ 103.57 | 0.29 % | $ 19.5 B | ||
|
Guardant Health
GH
|
1.15 B | $ 85.49 | 1.75 % | $ 10.7 B | ||
|
Global Cord Blood Corporation
CO
|
-6.07 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
-5.38 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-11.1 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-1.35 B | - | 0.12 % | $ 80.1 M | ||
|
Fulgent Genetics
FLGT
|
-53.3 M | $ 14.77 | 0.61 % | $ 447 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
769 M | - | - | $ 10.7 B | ||
|
Biodesix
BDSX
|
14.5 M | $ 17.88 | -6.63 % | $ 2.32 B | ||
|
Anixa Biosciences
ANIX
|
-1.04 M | $ 2.83 | -1.05 % | $ 91.8 K | ||
|
Danaher Corporation
DHR
|
14 B | $ 187.32 | 0.57 % | $ 134 B | ||
|
IQVIA Holdings
IQV
|
12 B | $ 164.72 | 1.1 % | $ 28.3 B | ||
|
Biocept
BIOC
|
-11.2 M | - | -13.05 % | $ 7.29 M | ||
|
Heska Corporation
HSKA
|
-153 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-11.2 M | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
-494 M | $ 118.94 | 2.92 % | $ 18.9 B | ||
|
Quest Diagnostics Incorporated
DGX
|
4.92 B | $ 199.7 | -0.46 % | $ 22.2 B | ||
|
QIAGEN N.V.
QGEN
|
1.31 B | - | - | $ 10.6 B | ||
|
Agilent Technologies
A
|
1.24 B | $ 111.51 | -0.06 % | $ 33.9 B | ||
|
BioNano Genomics
BNGO
|
-2.64 M | $ 1.11 | -0.89 % | $ 1.41 M | ||
|
DarioHealth Corp.
DRIO
|
-12.1 M | $ 9.0 | -0.99 % | $ 255 M | ||
|
Neogen Corporation
NEOG
|
751 M | $ 9.09 | -2.78 % | $ 1.97 B | ||
|
National Research Corporation
NRC
|
71.3 M | $ 16.52 | 0.12 % | $ 370 M | ||
|
Chembio Diagnostics
CEMI
|
-17.2 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
-11.6 M | - | - | $ 9.42 M | ||
|
Pacific Biosciences of California
PACB
|
-6.67 M | $ 1.33 | 4.72 % | $ 399 M | ||
|
Co-Diagnostics
CODX
|
-11.9 M | - | - | $ 79.8 M | ||
|
Medpace Holdings
MEDP
|
-360 M | $ 450.41 | 1.48 % | $ 13 B | ||
|
Celcuity
CELC
|
82.8 M | $ 114.22 | 3.11 % | $ 4.51 B | ||
|
DermTech
DMTK
|
-33.6 M | - | -11.32 % | $ 2.94 M | ||
|
Mettler-Toledo International
MTD
|
2.06 B | $ 1 173.74 | 0.49 % | $ 24.2 B | ||
|
Personalis
PSNL
|
-48.8 M | $ 6.72 | 1.97 % | $ 398 M | ||
|
NeoGenomics
NEO
|
187 M | $ 7.88 | -1.25 % | $ 1.01 B | ||
|
Enzo Biochem
ENZ
|
-51.3 M | - | -8.98 % | $ 14.8 K | ||
|
Natera
NTRA
|
-177 M | $ 187.85 | -1.29 % | $ 18.5 B | ||
|
Sotera Health Company
SHC
|
1.79 B | $ 13.42 | 0.71 % | $ 3.81 B | ||
|
Invitae Corporation
NVTA
|
-239 M | - | - | $ 21.2 M | ||
|
OPKO Health
OPK
|
-411 M | $ 1.19 | 2.59 % | $ 826 M |